IN2015DN01815A - - Google Patents

Info

Publication number
IN2015DN01815A
IN2015DN01815A IN1815DEN2015A IN2015DN01815A IN 2015DN01815 A IN2015DN01815 A IN 2015DN01815A IN 1815DEN2015 A IN1815DEN2015 A IN 1815DEN2015A IN 2015DN01815 A IN2015DN01815 A IN 2015DN01815A
Authority
IN
India
Prior art keywords
rory
formula
modulators
provides
tautomers
Prior art date
Application number
Other languages
English (en)
Inventor
Christian Gege
Olaf Kinzel
Christoph Steeneck
Gerald Kleymann
Thomas Hoffmann
Original Assignee
Phenex Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46754230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2015DN01815(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Phenex Pharmaceuticals Ag filed Critical Phenex Pharmaceuticals Ag
Publication of IN2015DN01815A publication Critical patent/IN2015DN01815A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IN1815DEN2015 2012-08-09 2013-05-29 IN2015DN01815A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261681296P 2012-08-09 2012-08-09
EP12005789 2012-08-09
PCT/EP2013/001594 WO2014023367A1 (en) 2012-08-09 2013-05-29 Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor ror gamma

Publications (1)

Publication Number Publication Date
IN2015DN01815A true IN2015DN01815A (ko) 2015-05-29

Family

ID=46754230

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1815DEN2015 IN2015DN01815A (ko) 2012-08-09 2013-05-29

Country Status (28)

Country Link
US (1) US9458104B2 (ko)
EP (2) EP2882710B1 (ko)
JP (1) JP6097829B2 (ko)
KR (1) KR101732973B1 (ko)
CN (1) CN104603105B (ko)
AR (1) AR091193A1 (ko)
AU (1) AU2013301914B2 (ko)
BR (1) BR112015002738A2 (ko)
CA (1) CA2879478C (ko)
CL (1) CL2015000300A1 (ko)
CO (1) CO7310529A2 (ko)
EA (1) EA027953B9 (ko)
GT (1) GT201500024A (ko)
HK (1) HK1211584A1 (ko)
IL (1) IL236695A (ko)
IN (1) IN2015DN01815A (ko)
JO (1) JO3215B1 (ko)
MX (1) MX364453B (ko)
NO (1) NO344067B1 (ko)
NZ (1) NZ704512A (ko)
PE (1) PE20150463A1 (ko)
PH (1) PH12015500142A1 (ko)
SG (1) SG11201500955RA (ko)
TW (2) TWI488839B (ko)
UA (1) UA115145C2 (ko)
UY (1) UY34833A (ko)
WO (1) WO2014023367A1 (ko)
ZA (1) ZA201500534B (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI659019B (zh) * 2014-02-28 2019-05-11 日商帝人製藥股份有限公司 吡唑醯胺衍生物
US9868724B2 (en) * 2014-05-28 2018-01-16 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2015188073A1 (en) * 2014-06-06 2015-12-10 Research Triangle Institute Apelin receptor (apj) agonists and uses thereof
JOP20200117A1 (ar) 2014-10-30 2017-06-16 Janssen Pharmaceutica Nv كحولات ثلاثي فلوروميثيل كمُعدلات للمستقبل النووي جاما تي المرتبط بحمض الريتيونَويك ROR?t
PT3212641T (pt) 2014-10-30 2019-02-11 Janssen Pharmaceutica Nv Tiazoles como moduladores de rorãt
EP3101006A1 (en) * 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3170822A1 (en) 2015-11-18 2017-05-24 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
US10100059B2 (en) 2015-12-09 2018-10-16 Research Triangle Institute Apelin receptor (APJ) agonists and uses thereof
US20200288710A1 (en) * 2016-03-15 2020-09-17 Bayer Cropscience Aktiengesellschaft Substituted sulphonamides for controlling animal pests
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
KR102541080B1 (ko) * 2016-10-12 2023-06-08 리서치 트라이앵글 인스티튜트 복소환식 아펠린 수용체(apj) 작용제 및 이의 용도
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
JP2020059651A (ja) * 2016-12-26 2020-04-16 科研製薬株式会社 ピラゾール誘導体及びそれを含有する医薬
JP2020142989A (ja) * 2017-06-21 2020-09-10 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 イミダゾール誘導体及びそれを含有する医薬
CN110997654B (zh) 2017-07-28 2023-08-15 诺华股份有限公司 吲哚衍生物及其用途
CN109485595B (zh) * 2017-09-12 2022-05-27 江苏恒瑞医药股份有限公司 亲水性基团取代的吲哚甲酰胺类衍生物、其制备方法及其在医药上的应用
CN111094278B (zh) 2017-09-13 2023-07-14 诺华股份有限公司 二苯基衍生物及其用途
CA3087994A1 (en) * 2018-02-28 2019-09-06 Japan Tobacco Inc. 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
CN112292373A (zh) * 2018-06-18 2021-01-29 詹森药业有限公司 作为RORγt的调节剂的吡啶基吡唑类
JP2021528405A (ja) 2018-06-18 2021-10-21 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγｔのモジュレータとしてのアミド置換チアゾール
CN112292183A (zh) * 2018-06-18 2021-01-29 詹森药业有限公司 作为RORγt的调节剂的6-氨基吡啶-3-基吡唑
CN112334450A (zh) * 2018-06-18 2021-02-05 詹森药业有限公司 作为RORγt的调节剂的苯基和吡啶基取代的咪唑
CN111484505B (zh) * 2019-01-28 2022-11-15 正大天晴药业集团股份有限公司 一种双环RORγ抑制剂的盐酸盐结晶型
UY38794A (es) 2019-07-23 2021-02-26 Bayer Ag Novedosos compuestos de heteroaril-triazol como plaguicidas
WO2021089673A1 (de) 2019-11-07 2021-05-14 Bayer Aktiengesellschaft Substituierte sulfonylamide zur bekämpfung tierischer schädlinge
TW202136248A (zh) 2019-11-25 2021-10-01 德商拜耳廠股份有限公司 作為殺蟲劑之新穎雜芳基-三唑化合物
TW202208347A (zh) 2020-05-06 2022-03-01 德商拜耳廠股份有限公司 作為殺蟲劑之新穎雜芳基三唑化合物
EP4212531A1 (en) 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9012936D0 (en) * 1990-06-11 1990-08-01 Fujisawa Pharmaceutical Co Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
HRP950330A2 (en) 1994-07-05 1997-10-31 Ciba Geigy Ag New herbicides
US5776954A (en) 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
US6413997B1 (en) 1998-10-23 2002-07-02 Dow Agrosciences Llc 3-(substituted phenyl)-5-(substituted heterocyclyl)-1,2,4-triazole compounds
MXPA02005100A (es) 1999-10-18 2003-09-25 Alexipharma Inc Derivados de pirazol antagonistas de receptor de canabinoide.
US8084467B2 (en) 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7393842B2 (en) 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
EP1259504A1 (en) 2000-03-03 2002-11-27 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents
SE0102315D0 (sv) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
JP2005507875A (ja) 2001-08-31 2005-03-24 ユニバーシティ オブ コネチカット カンナビノイド受容体に作用する新規なピラゾール類似体
WO2003037335A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 5-heteroatom-substituted pyrazoles
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
JP2005538110A (ja) 2002-07-29 2005-12-15 ニトロメッド インコーポレーティッド シクロオキシゲナーゼ−２選択的阻害剤、組成物、および使用方法
EP1545515A1 (en) 2002-08-12 2005-06-29 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
EP1433788A1 (en) 2002-12-23 2004-06-30 Aventis Pharma Deutschland GmbH Pyrazole-derivatives as factor Xa inhibitors
EP1583742B1 (en) * 2003-01-02 2009-12-02 F. Hoffmann-La Roche Ag Cb 1 receptour inverse agonists
CA2520804A1 (en) 2003-04-03 2004-10-28 Merck & Co., Inc. Biaryl substituted pyrazoles as sodium channel blockers
KR20060005378A (ko) 2003-04-21 2006-01-17 다이이찌 세이야꾸 가부시기가이샤 ５원 복소환 유도체
EP1664052B1 (en) 2003-08-15 2009-02-18 AstraZeneca AB Fused heterocycles as inhibitors of glutamate racemase (muri)
DE602005014632D1 (de) 2004-05-10 2009-07-09 Hoffmann La Roche Pyrrol- bzw. imidazolamide zur behandlung von obesitas
CN101228160A (zh) * 2004-06-30 2008-07-23 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吖吲哚
WO2006004984A1 (en) 2004-06-30 2006-01-12 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of protein kinases
KR100869393B1 (ko) 2004-08-26 2008-11-21 화이자 인코포레이티드 단백질 키나제 억제제로서 피라졸-치환된 아미노헤테로아릴화합물
EP1881991A1 (en) 2005-05-19 2008-01-30 Cv Therapeutics, Inc. A1 adenosine receptor agonists
WO2006133926A1 (en) 2005-06-17 2006-12-21 Carex Sa Pyrazole derivates as cannabinoid receptor modulators
AU2006261841B8 (en) 2005-06-27 2012-12-06 Exelixis Patent Company Llc Pyrazole based LXR modulators
TW200720255A (en) * 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
WO2007024744A2 (en) 2005-08-21 2007-03-01 Exelixis, Inc. Heterocyclic carboxamide compounds as steroid nuclear receptor ligands
US20100256357A1 (en) * 2006-08-09 2010-10-07 Agouron Pharmaceuticals, Inc. Heterocycles useful as inhibitors of carbonic anhydrase
JP5437812B2 (ja) 2006-12-18 2014-03-12 ７ティーエム ファーマ エイ／エス Ｃｂ１受容体モジュレーター
EP1946778A1 (en) 2007-01-16 2008-07-23 Laboratorios del Dr. Esteve S.A. Active substance combination for the treatment of diabetes
WO2008092942A2 (en) 2007-02-02 2008-08-07 Neurosearch A/S Pyridinyl-pyrazole derivatives and their use as potassium channel modulators
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
WO2009037247A1 (en) 2007-09-17 2009-03-26 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
KR100917037B1 (ko) 2007-11-01 2009-09-10 한국과학기술연구원 피라졸릴카르복스아미도알킬피페라진 유도체 및 이의제조방법
EP2238127B1 (en) 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
US20090197895A1 (en) 2008-01-31 2009-08-06 The Scripps Research Institute Oxazole-pyrrole-piperazine alpha-helix mimetic
CN101544631B (zh) 2008-03-26 2012-05-23 中国科学院上海药物研究所 吡唑类5-脂氧酶小分子抑制剂及其制备方法、药物组合物和应用
US8895558B2 (en) 2008-10-02 2014-11-25 Green Cross Corporation Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders
US20110230536A1 (en) 2008-10-24 2011-09-22 Calcimedica, Inc. Phenylpyrazole inhibitors of store operated calcium release
EP2181710A1 (en) 2008-10-28 2010-05-05 Phenex Pharmaceuticals AG Ligands for modulation of orphan receptor-gamma (NR1F3) activity
JP2012513409A (ja) 2008-12-23 2012-06-14 アボット・ラボラトリーズ 抗ウイルス化合物
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
DK2486018T3 (da) 2009-10-07 2019-07-29 Karo Pharma Ab Substituerede pyrazoler som østrogenreceptorligander
TWI532725B (zh) 2010-01-26 2016-05-11 賽諾菲阿凡提斯公司 經氧取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途
EP2368886A1 (en) 2010-03-01 2011-09-28 Phenex Pharmaceuticals AG Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease
US9492439B2 (en) 2010-03-11 2016-11-15 New York University Amido compounds as RORγt modulators and uses thereof
US9101600B2 (en) 2010-03-11 2015-08-11 New York University Compounds as RORγt modulators and uses thereof
WO2011115892A1 (en) 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012028100A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
EP2638014B1 (en) 2010-11-08 2017-01-04 Lycera Corporation N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ror-gamma activity and the treatment of diseases
US8722709B2 (en) 2010-11-10 2014-05-13 Boehringer Ingelheim International Gmbh Mineralocorticoid receptor antagonists
US9505798B2 (en) 2010-11-29 2016-11-29 New York University Steroid compounds as RORyt modulators and uses thereof
WO2012100734A1 (en) * 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
WO2012100732A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof
MX353762B (es) 2011-01-28 2018-01-26 4Sc Discovery Gmbh Inhibicion de il17 e ifn-gamma para el tratamiento de inflamacion autoinmune.
US8354436B2 (en) 2011-01-28 2013-01-15 4Sc Discovery Gmbh IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
CA2736441A1 (en) 2011-04-06 2012-10-06 The Regents Of The University Of California Pyrazolylthiazole compounds as .delta.f508-cystic fibrosis transmembrane conductance regulator correctors
US9284298B2 (en) 2011-04-11 2016-03-15 Nerviano Medical Sciences S.R.L. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
EP2511263A1 (en) 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
WO2012145254A2 (en) 2011-04-16 2012-10-26 Board Of Regents, The University Of Texas System Methods of using inhibitors of rorϒt to treat disease
SG194526A1 (en) 2011-04-28 2013-12-30 Japan Tobacco Inc Amide compound and pharmaceutical application therefor
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
BR112013033617B1 (pt) 2011-06-27 2021-10-26 Galderma Research & Development Uso de mrna, método para o diagnóstico de acne, métodos para o monitoramento da progressão ou variação de acne e da eficácia de um tratamento para tratar acne, e de triagem in vitro para a identificação de inibidores de diferenciação de células th17
WO2013000871A1 (en) 2011-06-27 2013-01-03 Galderma Research & Development New th-17 differentiation markers for rosacea and uses thereof
KR20140049019A (ko) 2011-07-26 2014-04-24 사노피 ３―헤테로아로일아미노―프로피온산 유도체 및 이의 약제로서의 용도
US9156837B2 (en) 2011-07-29 2015-10-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
US20140315881A1 (en) 2011-07-29 2014-10-23 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2013019653A1 (en) 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
US20140256740A1 (en) 2011-07-29 2014-09-11 Tempero Pharmaceuticals, Inc. Compounds and methods
US20140155419A1 (en) 2011-07-29 2014-06-05 Erkan Baloglu Compounds and methods
WO2013029338A1 (en) 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
US9765063B2 (en) 2011-09-09 2017-09-19 New York University Amido compounds as RORγt modulators and uses thereof
DK2758060T3 (en) 2011-09-19 2018-03-05 Eth Zuerich ROR gamma modulators for the treatment of diabetes II complications
EP2759533B1 (en) 2011-09-22 2017-08-02 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
GB201116641D0 (en) 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
WO2013079223A1 (en) * 2011-12-02 2013-06-06 Phenex Pharmaceuticals Ag Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rorϒ, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases
NZ702539A (en) 2012-05-31 2016-11-25 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]

Also Published As

Publication number Publication date
NO344067B1 (en) 2019-08-26
BR112015002738A2 (pt) 2018-05-22
MX364453B (es) 2019-04-26
JP6097829B2 (ja) 2017-03-15
CL2015000300A1 (es) 2015-07-10
AU2013301914B2 (en) 2016-08-18
CN104603105B (zh) 2017-09-08
JO3215B1 (ar) 2018-03-08
JP2015524449A (ja) 2015-08-24
NO20150112A1 (en) 2015-01-23
UY34833A (es) 2013-12-31
AR091193A1 (es) 2015-01-21
US9458104B2 (en) 2016-10-04
SG11201500955RA (en) 2015-03-30
CA2879478A1 (en) 2014-02-13
EA201590092A1 (ru) 2015-08-31
UA115145C2 (uk) 2017-09-25
KR101732973B1 (ko) 2017-05-08
WO2014023367A1 (en) 2014-02-13
EA027953B9 (ru) 2018-01-31
PH12015500142B1 (en) 2015-03-16
CO7310529A2 (es) 2015-06-30
HK1211584A1 (en) 2016-05-27
AU2013301914A8 (en) 2015-02-12
EP2882710B1 (en) 2016-09-07
EP2882710A1 (en) 2015-06-17
ZA201500534B (en) 2016-10-26
TWI488839B (zh) 2015-06-21
IL236695A (en) 2017-07-31
TW201406723A (zh) 2014-02-16
US20150344423A1 (en) 2015-12-03
NZ704512A (en) 2016-09-30
GT201500024A (es) 2017-08-24
KR20150040354A (ko) 2015-04-14
CN104603105A (zh) 2015-05-06
PH12015500142A1 (en) 2015-03-16
CA2879478C (en) 2017-08-22
EP3118189A1 (en) 2017-01-18
MX2015001728A (es) 2015-04-14
EA027953B1 (ru) 2017-09-29
AU2013301914A1 (en) 2015-02-05
PE20150463A1 (es) 2015-04-23
TW201527278A (zh) 2015-07-16
IL236695A0 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
IN2015DN01815A (ko)
PH12014502570A1 (en) Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
IN2015KN00414A (ko)
IN2014MN02106A (ko)
TN2014000357A1 (en) Heterocyclyl compounds
TN2015000250A1 (en) Novel benzimidazole derivatives as ep4 antagonists
PH12014502414A1 (en) Novel compounds
IN2014MN02598A (ko)
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
IN2014KN01075A (ko)
MX2014013499A (es) Moduladores alostericos de receptor alfa 7 nicotinico de acetilcolina, sus derivados y usos de los mismos.
IN2015DN01119A (ko)
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
MX2017003156A (es) Inhibidores espirociclicos de catepsina c.
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
GEP20156319B (en) Asymmetric ureas and medical uses thereof
EA036542B9 (ru) Галоген-замещенные пиперидины в качестве модуляторов орексинового рецептора
PH12014501943A1 (en) Novel compounds for the treatment of dyslipidemia and related diseases
MX2019006942A (es) Agonistas de receptores de oxitocina no peptidicos.
IN2013MU01124A (ko)
ECSP15007708A (es) Heterociclos de 5 miembros que contienen nitrógeno sustituidos por carboxamida o sulfonamida como moduladores para el receptor nuclear huérfano ror[gamma]
ECSP14033496A (es) Tiazoles sustituidos por carboxamida o sulfonamida y derivados relacionados como moduladores para el receptor nuclear huérfano ror[gamma]
MX2019009243A (es) Antagonistas il-4r para usarse en el tratamiento o previncion de asma persistente y asma severa.
TR201900156T4 (tr) Tüberküloz ve ilgili hastalıkların tedavisi için kinolil hidrazonlar.
MX2015006807A (es) Metodo de preparacion de formas cristalinas de la 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1-oxidopiridin-4-il)-5-metox ipiridin-2-carboxamida y sus formas cristalinas.